Perceptive Advisors LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Perceptive Advisors LLC reported 99 stock positions worth $4.7 billion. Its top holding was Arcellx (ACLX) at 7.0% of the portfolio, followed by Nuvalent Class A (NUVL, 6.5%) and Amicus Therapeutics (FOLD, 6.4%). Compared with Q2 2024, it opened 13 new positions, sold out of 18, added to 23 and reduced 25. The biggest buy was Verona Pharma (VRNA, shares +160%) and the biggest sale an exit from Cerevel Therapeutics (CERE).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001224962
- Portfolio Value
- $4.7B (Q3 2024)
- SEC Filing
- 0001012975-24-000488 ↗ filed Nov 14, 2024
Holdings Value
Holdings 99 stocks · $4.7B
| ACLX Arcellx Inc. | 6.97% | 3,888,669 | $324.7M | Reduce -0.0% |
| NUVL Nuvalent Inc. Class A | 6.54% | 2,979,235 | $304.8M | Add +16.9% |
| FOLD Amicus Therapeutics Inc. | 6.43% | 28,057,456 | $299.7M | No change |
| IOVA Iovance Biotherapeutics Inc. | 5.36% | 26,617,709 | $249.9M | Add +2.6% |
| PCVX Vaxcyte Inc. | 4.97% | 2,027,608 | $231.7M | Add +8.9% |
| RYTM Rhythm Pharmaceuticals Inc. | 4.00% | 3,560,214 | $186.5M | Add +3.3% |
| VRNA Verona Pharma Ltd. | 3.90% | 6,315,933 | $181.7M | Add +159.5% |
| SLNO Soleno Therapeutics Inc. | 3.47% | 3,204,976 | $161.8M | No change |
| ITCI Intra-Cellular Therapies Inc. | 2.55% | 1,622,215 | $118.7M | Reduce -5.5% |
| APGE Apogee Therapeutics Inc. | 2.54% | 2,015,007 | $118.4M | Reduce -4.3% |
| VKTX Viking Therapeutics Inc. | 2.31% | 1,699,987 | $107.6M | Add +135.7% |
| CNTA Centessa Pharmaceuticals Ltd. | 2.16% | 6,282,290 | $100.5M | Add +59.7% |
| IMTX Immatics NV | 1.98% | 8,086,159 | $92.3M | No change |
| EOLS Evolus Inc. | 1.86% | 5,356,622 | $86.8M | Reduce -6.9% |
| SYRE Spyre Therapeutics Inc. | 1.81% | 2,872,547 | $84.5M | Reduce -5.2% |
| AORT Artivion Inc. | 1.60% | 2,793,703 | $74.4M | No change |
| BHVN Biohaven Ltd. | 1.59% | 1,485,232 | $74.2M | No change |
| ATXS Astria Therapeutics Inc. | 1.53% | 6,485,420 | $71.4M | No change |
| AXSM Axsome Therapeutics Inc. | 1.51% | 782,844 | $70.4M | Add +70.5% |
| APLT Applied Therapeutics Inc. | 1.46% | 8,005,000 | $68.0M | No change |
| CRGX Cargo Therapeutics Inc. | 1.46% | 3,683,004 | $68.0M | No change |
| IMVT Immunovant Inc. | 1.46% | 2,378,762 | $67.8M | Add +23.6% |
| PRAX Praxis Precision Medicines I | 1.44% | 1,164,035 | $67.0M | Add +55.2% |
| ARGX Argenx SE - ADR | 1.38% | 118,839 | $64.4M | Add +661.8% |
| VRDN Viridian Therapeutics Inc. | 1.37% | 2,812,665 | $64.0M | Add +72.4% |
| EWTX Edgewise Therapeutics Inc. | 1.33% | 2,330,294 | $62.2M | Add +25.5% |
| PTGX Protagonist Therapeutics Inc. | 1.33% | 1,374,563 | $61.9M | Add +8.3% |
| MGTX Meiragtx Holdings PLC | 1.12% | 12,581,103 | $52.4M | Add +11.0% |
| ALDX Aldeyra Therapeutics Inc. | 1.07% | 9,275,851 | $50.0M | No change |
| AKRO Akero Therapeutics Inc. | 1.06% | 1,714,806 | $49.2M | Add +14.3% |
| SLDB Solid Biosciences Inc. | 1.03% | 6,906,646 | $48.1M | No change |
| TARS Tarsus Pharmaceuticals Inc. | 0.91% | 1,296,416 | $42.6M | No change |
| ACRV Acrivon Therapeutics Inc. | 0.81% | 5,360,858 | $37.5M | No change |
| CRNX Crinetics Pharmaceuticals Inc. | 0.79% | 724,698 | $37.0M | Reduce -50.9% |
| NAUT Nautilus Biotechnology Inc. | 0.77% | 12,594,211 | $35.9M | No change |
| CELC Celcuity Inc. | 0.76% | 2,362,279 | $35.2M | No change |
| PODD Insulet Corp. | 0.71% | 142,269 | $33.1M | New |
| ORKA Oruka Therapeutics Inc. | 0.65% | 1,235,187 | $30.3M | New |
| CTNM Contineum Therapeutics Inc. Class A | 0.62% | 1,516,668 | $29.0M | Reduce -3.2% |
| OCUL Ocular Therapeutix Inc. | 0.62% | 3,324,468 | $28.9M | No change |
| ISRG Intuitive Surgical Inc. | 0.61% | 58,119 | $28.6M | Reduce -6.0% |
| NTRA Natera Inc. | 0.60% | 220,000 | $27.9M | Reduce -58.5% |
| CGON CG Oncology Inc. | 0.59% | 733,695 | $27.7M | No change |
| ZYME Zymeworks Inc. | 0.59% | 2,180,020 | $27.4M | Add +30.7% |
| DYN Dyne Therapeutics Inc. | 0.55% | 718,144 | $25.8M | New |
| ADGM Adagio Medical Holdings Inc. | 0.54% | 9,812,419 | $25.3M | New |
| ARVN Arvinas Inc. | 0.54% | 1,027,749 | $25.3M | No change |
| PRCT Procept Biorobotics Corp. | 0.54% | 315,659 | $25.3M | Add +49.8% |
| NBIX Neurocrine Biosciences Inc. | 0.52% | 212,228 | $24.5M | Reduce -67.3% |
| OBIO Orchestra Biomed Holdings Inc. | 0.51% | 4,592,556 | $23.6M | Add +80.4% |
| TIL Instil Bio Inc. | 0.50% | 345,545 | $23.3M | New |
| LIVN Livanova PLC | 0.48% | 429,000 | $22.5M | Reduce -3.4% |
| SWTX Springworks Therapeutics Inc. | 0.48% | 692,263 | $22.2M | Reduce -58.1% |
| MDT Medtronic PLC | 0.47% | 245,332 | $22.1M | Reduce -50.0% |
| ADMA Adma Biologics Inc. | 0.45% | 1,060,200 | $21.2M | Reduce -61.7% |
| XENE Xenon Pharmaceuticals Inc. | 0.44% | 524,930 | $20.7M | Reduce -10.0% |
| ZBIO Zenas Biopharma Inc. | 0.42% | 1,144,035 | $19.4M | New |
| IRON Disc Medicine Inc. | 0.41% | 387,017 | $19.0M | Reduce -30.1% |
| RCKT Rocket Pharmaceuticals Inc. | 0.37% | 931,851 | $17.2M | Reduce -25.3% |
| INBX Inhibrx Biosciences Inc. | 0.36% | 1,064,026 | $16.7M | No change |
| RAPP Rapport Therapeutics Inc. | 0.33% | 748,183 | $15.3M | No change |
| MRUS Merus NV | 0.32% | 300,000 | $15.0M | No change |
| INSM Insmed Inc. | 0.28% | 180,000 | $13.1M | No change |
| ICLR Icon PLC | 0.27% | 44,353 | $12.7M | Add +41.9% |
| ARQT Arcutis Biotherapeutics Inc. | 0.27% | 1,358,500 | $12.6M | Reduce -12.8% |
| PEPG Pepgen Inc. | 0.26% | 1,410,438 | $12.1M | No change |
| TYRA Tyra Biosciences Inc. | 0.26% | 511,226 | $12.0M | Reduce -49.3% |
| XNCR Xencor Inc. | 0.23% | 527,671 | $10.6M | New |
| VRCA Verrica Pharmaceuticals Inc. | 0.22% | 7,099,182 | $10.3M | No change |
| ROIV Roivant Sciences Ltd. | 0.21% | 847,745 | $9.8M | New |
| AVBP Arrivent Biopharma Inc. | 0.21% | 415,000 | $9.8M | No change |
| EXAS Exact Sciences Corp. | 0.18% | 125,000 | $8.5M | New |
| EYPT Eyepoint Inc. | 0.18% | 1,037,274 | $8.3M | Add +62.0% |
| ALLO Allogene Therapeutics Inc. | 0.16% | 2,725,000 | $7.6M | No change |
| AMLX Amylyx Pharmaceuticals Inc. | 0.15% | 2,125,649 | $6.9M | New |
| BCYC Bicycle Therapeutics PLC-ADR | 0.12% | 255,994 | $5.8M | Reduce -55.3% |
| VERU Veru Inc. | 0.12% | 7,283,157 | $5.6M | Add +3.1% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.11% | 500,000 | $5.2M | No change |
| BDSX Biodesix Inc. | 0.08% | 2,173,880 | $3.9M | No change |
| DTIL Precision Biosciences Inc. | 0.08% | 426,293 | $3.8M | No change |
| MREO Mereo Biopharma Group PL-ADR | 0.07% | 815,722 | $3.4M | Reduce -34.9% |
| LYRA Lyra Therapeutics Inc. | 0.07% | 12,757,562 | $3.3M | No change |
| NBTX Nanobiotix SA - ADR | 0.07% | 555,066 | $3.2M | No change |
| ABSI Absci Corp. | 0.06% | 700,000 | $2.7M | No change |
| ATHIRA PHARMA INC | 0.05% | 5,402,964 | $2.4M | No change |
| XFOR X4 Pharmaceuticals Inc. | 0.05% | 3,545,454 | $2.4M | No change |
| NVNO Envveno Medical Corporation | 0.05% | 694,315 | $2.3M | Add +11.4% |
| KYMR Kymera Therapeutics Inc. | 0.05% | 46,213 | $2.2M | New |
| TRINITY BIOTECH INVT LTD | 0.04% | 1,800,000 | $2.0M | No change |
| PYXS Pyxis Oncology Inc. | 0.04% | 508,462 | $1.9M | New |
| IRTC Irhythm Holdings Inc. | 0.04% | 22,591 | $1.7M | Reduce -35.8% |
| GPCR Structure Therapeutics Inc. | 0.03% | 34,852 | $1.5M | No change |
| LXEO Lexeo Therapeutics Inc. | 0.03% | 139,835 | $1.3M | New |
| FATE Fate Therapeutics Inc. | 0.03% | 345,575 | $1.2M | No change |
| OMIC Singular Genomics Systems Inc. | 0.02% | 50,896 | $798K | Reduce -28.2% |
| KYTX Kyverna Therapeutics Inc. | 0.02% | 150,000 | $734K | No change |
| FBRX Forte Biosciences Inc. | 0.01% | 95,742 | $535K | Reduce -26.7% |
| SYRS Syros Pharmaceuticals Inc. | 0.01% | 116,754 | $251K | No change |
| CMAXQ Caremax Inc. | 0.00% | 100,000 | $170K | Reduce -18.5% |
Options reported separately and not counted above: XBI puts ($39.5M), VRNA calls ($7.2M), VRNA puts ($7.2M), FLNA puts ($5.4M), FULC calls ($5.4M), NVAX puts ($1.3M).
Other holdings (3): bonds, preferreds, convertibles and warrants · $37K (not counted above)
Total filed on the 13F, all lines: $4.7B.
Portfolio Sells Q2 2024 → Q3 2024
| CERE Cerevel Therapeutics Holding | Sold out | 0.00% | −10.65 |
| MDGL Madrigal Pharmaceuticals Inc. | Sold out | 0.00% | −1.79 |
| NBIX Neurocrine Biosciences Inc. | Reduce -67.3% | 0.52% | −1.64 |
| SWTX Springworks Therapeutics Inc. | Reduce -58.1% | 0.48% | −1.03 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -50.9% | 0.79% | −0.80 |
| NTRA Natera Inc. | Reduce -58.5% | 0.60% | −0.79 |
| BBIO Bridgebio Pharma Inc. | Sold out | 0.00% | −0.74 |
| MDT Medtronic PLC | Reduce -50.0% | 0.47% | −0.46 |
| CGEM Cullinan Therapeutics Inc. | Sold out | 0.00% | −0.32 |
| ADMA Adma Biologics Inc. | Reduce -61.7% | 0.45% | −0.29 |
| ITCI Intra-Cellular Therapies Inc. | Reduce -5.5% | 2.55% | −0.29 |
| RCKT Rocket Pharmaceuticals Inc. | Reduce -25.3% | 0.37% | −0.28 |
| TEM Tempus AI Inc. Class A | Sold out | 0.00% | −0.23 |
| IRON Disc Medicine Inc. | Reduce -30.1% | 0.41% | −0.19 |
| ENGN Engene Holdings Inc. | Sold out | 0.00% | −0.18 |
| SPRY Ars Pharmaceuticals Inc. | Sold out | 0.00% | −0.18 |
| BCYC Bicycle Therapeutics PLC-ADR | Reduce -55.3% | 0.12% | −0.16 |
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −0.14 |
| RXRX Recursion Pharmaceuticals-A | Sold out | 0.00% | −0.14 |
| TYRA Tyra Biosciences Inc. | Reduce -49.3% | 0.26% | −0.13 |
| CABA Cabaletta Bio Inc. | Sold out | 0.00% | −0.11 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -10.0% | 0.44% | −0.11 |
| LIVN Livanova PLC | Reduce -3.4% | 0.48% | −0.10 |
| SKYE Skye Bioscience Inc. | Sold out | 0.00% | −0.10 |
| ARQT Arcutis Biotherapeutics Inc. | Reduce -12.8% | 0.27% | −0.08 |
| FHTX Foghorn Therapeutics Inc. | Sold out | 0.00% | −0.08 |
| IRTC Irhythm Holdings Inc. | Reduce -35.8% | 0.04% | −0.06 |
| ISRG Intuitive Surgical Inc. | Reduce -6.0% | 0.61% | −0.05 |
| XBI SS SPDR S&P Biotech ETF | Sold out | 0.00% | −0.05 |
| CTNM Contineum Therapeutics Inc. Class A | Reduce -3.2% | 0.62% | −0.04 |
| RVNC Revance Therapeutics Inc. | Sold out | 0.00% | −0.04 |
| MREO Mereo Biopharma Group PL-ADR | Reduce -34.9% | 0.07% | −0.04 |
| FBRX Forte Biosciences Inc. | Reduce -26.7% | 0.01% | −0.03 |
| EGRX Eagle Pharmaceuticals Inc. | Sold out | 0.00% | −0.02 |
| VBIVQ Vbi Vaccines Inc. | Sold out | 0.00% | −0.02 |
| TCMD Tactile Systems Technology I | Sold out | 0.00% | −0.02 |
| AXGN Axogen Inc. | Sold out | 0.00% | −0.01 |
| CMAXQ Caremax Inc. | Reduce -18.5% | 0.00% | −0.00 |
| OMIC Singular Genomics Systems Inc. | Reduce -28.2% | 0.02% | +0.00 |
| SYRE Spyre Therapeutics Inc. | Reduce -5.2% | 1.81% | +0.09 |
| EOLS Evolus Inc. | Reduce -6.9% | 1.86% | +0.35 |
| APGE Apogee Therapeutics Inc. | Reduce -4.3% | 2.54% | +0.54 |
| ACLX Arcellx Inc. | Reduce -0.0% | 6.97% | +1.79 |
Portfolio Buys Q2 2024 → Q3 2024
| VRNA Verona Pharma Ltd. | Add +159.5% | 3.90% | +3.05 |
| NUVL Nuvalent Inc. Class A | Add +16.9% | 6.54% | +1.87 |
| PCVX Vaxcyte Inc. | Add +8.9% | 4.97% | +1.58 |
| VKTX Viking Therapeutics Inc. | Add +135.7% | 2.31% | +1.39 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +59.7% | 2.16% | +1.30 |
| ARGX Argenx SE - ADR | Add +661.8% | 1.38% | +1.22 |
| VRDN Viridian Therapeutics Inc. | Add +72.4% | 1.37% | +0.86 |
| PODD Insulet Corp. | New | 0.71% | +0.71 |
| PRAX Praxis Precision Medicines I | Add +55.2% | 1.44% | +0.69 |
| ORKA Oruka Therapeutics Inc. | New | 0.65% | +0.65 |
| AXSM Axsome Therapeutics Inc. | Add +70.5% | 1.51% | +0.62 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +3.3% | 4.00% | +0.59 |
| DYN Dyne Therapeutics Inc. | New | 0.55% | +0.55 |
| ADGM Adagio Medical Holdings Inc. | New | 0.54% | +0.54 |
| EWTX Edgewise Therapeutics Inc. | Add +25.5% | 1.33% | +0.53 |
| TIL Instil Bio Inc. | New | 0.50% | +0.50 |
| ZBIO Zenas Biopharma Inc. | New | 0.42% | +0.42 |
| IOVA Iovance Biotherapeutics Inc. | Add +2.6% | 5.36% | +0.34 |
| PTGX Protagonist Therapeutics Inc. | Add +8.3% | 1.33% | +0.27 |
| ZYME Zymeworks Inc. | Add +30.7% | 0.59% | +0.24 |
| PRCT Procept Biorobotics Corp. | Add +49.8% | 0.54% | +0.23 |
| IMVT Immunovant Inc. | Add +23.6% | 1.46% | +0.23 |
| XNCR Xencor Inc. | New | 0.23% | +0.23 |
| ROIV Roivant Sciences Ltd. | New | 0.21% | +0.21 |
| AKRO Akero Therapeutics Inc. | Add +14.3% | 1.06% | +0.21 |
| EXAS Exact Sciences Corp. | New | 0.18% | +0.18 |
| AMLX Amylyx Pharmaceuticals Inc. | New | 0.15% | +0.15 |
| KYMR Kymera Therapeutics Inc. | New | 0.05% | +0.05 |
| EYPT Eyepoint Inc. | Add +62.0% | 0.18% | +0.04 |
| PYXS Pyxis Oncology Inc. | New | 0.04% | +0.04 |
| ICLR Icon PLC | Add +41.9% | 0.27% | +0.04 |
| LXEO Lexeo Therapeutics Inc. | New | 0.03% | +0.03 |
| OBIO Orchestra Biomed Holdings Inc. | Add +80.4% | 0.51% | +0.01 |
| VERU Veru Inc. | Add +3.1% | 0.12% | −0.02 |
| MGTX Meiragtx Holdings PLC | Add +11.0% | 1.12% | −0.03 |
| NVNO Envveno Medical Corporation | Add +11.4% | 0.05% | −0.03 |
Options Activity Q2 2024 → Q3 2024
| XBI SS SPDR S&P Biotech ETF | put | New | 400,000 | $39.5M |
| VRNA Verona Pharma Ltd. | call | New | 250,000 | $7.2M |
| VRNA Verona Pharma Ltd. | put | New | 250,000 | $7.2M |
| FULC Fulcrum Therapeutics Inc. | call | New | 1,500,000 | $5.4M |
| IMVT Immunovant Inc. | call | Sold out | 200,000 | $5.3Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 99 | $6.4B | PRAX, SYRE, CELC, ASND, RYTM |
| Q1 2026Amended | 89 | $5.0B | PRAX, CELC, ASND, ROIV, CNTA |
| Q4 2025 | 109 | $5.4B | PRAX, CELC, RYTM, ASND, APGE |
| Q3 2025 | 88 | $3.4B | RYTM, ASND, ACLX, CELC, NUVL |
| Q2 2025 | 80 | $2.7B | VRNA, ASND, ACLX, RYTM, NUVL |
| Q1 2025Amended | 84 | $2.8B | VRNA, ACLX, FOLD, EWTX, RYTM |
| Q4 2024 | 95 | $3.6B | VRNA, ACLX, FOLD, RYTM, NUVL |
| Q3 2024 | 99 | $4.7B | ACLX, NUVL, FOLD, IOVA, PCVX |
| Q2 2024Amended | 104 | $4.1B | CERE, FOLD, ACLX, IOVA, NUVL |
| Q1 2024Amended | 102 | $5.7B | CERE, FOLD, IOVA, ACLX, NUVL |